Last reviewed · How we verify
C-11 labeled nicotine
C-11 labeled nicotine is a radiotracer that binds to nicotinic acetylcholine receptors and allows visualization of receptor distribution and density in the brain using positron emission tomography (PET) imaging.
C-11 labeled nicotine is a radiotracer that binds to nicotinic acetylcholine receptors and allows visualization of receptor distribution and density in the brain using positron emission tomography (PET) imaging. Used for Research imaging of nicotinic acetylcholine receptor distribution and occupancy in the brain, Investigation of neuropsychiatric and neurodegenerative disorders involving cholinergic dysfunction.
At a glance
| Generic name | C-11 labeled nicotine |
|---|---|
| Sponsor | University of Cincinnati |
| Drug class | PET imaging agent / radiotracer |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry (research/diagnostic) |
| Phase | FDA-approved |
Mechanism of action
This is a research imaging agent, not a therapeutic drug. The carbon-11 radiolabel enables PET imaging to map nicotinic acetylcholine receptor availability and occupancy in vivo. It is used to study receptor pharmacology, disease pathology, and drug engagement in conditions affecting cholinergic neurotransmission.
Approved indications
- Research imaging of nicotinic acetylcholine receptor distribution and occupancy in the brain
- Investigation of neuropsychiatric and neurodegenerative disorders involving cholinergic dysfunction
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |